PubMed Health⌕ Search

Biomedical subjects

E R Pille

Publications and source records attributed to E R Pille.

47 records · Page 3Linked to original sources
PubMedDate not supplied

[Results of human immunization with a new rabies vaccine containing no neuroallergenic brain tissue factor].

Immunization with a vaccine prepared from sheep-brain-grown fixed rabies virus inactivated with beta-propiolactone was given to 146 subjects. The vaccine was by 80-90% purified from waste brain tissue substances (protein content less than 2 mg/ml) and showed no neuroallergenicity in guinea pig tests. Simultaneously 86 subjects were vaccinated with commercial Fermi vaccine. Immunization was performed according to the schedules accepted in the USSR. The new vaccine produced much fewer local reactions than Fermi vaccine (in 39.6% and 60.9% vaccinees, respectively) and 5 times as few systemic reactions (in 6.03% and 31.3% vaccinees, respectively). The antigenic potency of the new vaccine was as good as that of Fermi vaccine.

Adolescent↗
PubMedDate not supplied

[Reproduction of fixed rabies virus in a quail fibroblast culture growing in suspension].

Reproduction of culture variant of fixed rabies virus was studied in cultures of quail fibroblasts growing in roller suspension cultures, as well as in monolayer cultures of Japanese quail embryos fixed on DEAE-Sephadex A-50 particles. Titers of the virus in cultures on the microcarrier were found to be similar with those in roller monolayer cultures, namely 5.75--6.5 lg LD50/ml. In shaker and roller suspension cultures the virus titers were lower: 4.5--5.25 lg LD50/ml.

Animals↗
PubMedDate not supplied

[The antiviral action of recombinant forms of the human T-lymphocyte CD4 receptor].

A recombinant protein containing the first 179 N-terminus amino acids of human T-lymphocyte CD4-receptor was synthesized in E. coli cells. This recombinant protein was shown to interact with OKT4A and Leu3a monoclonal antibodies competing with HIV gp120 glycoprotein for binding with the native CD4 receptor. Experiments in vitro in human T-lymphocyte cultures showed that the recombinant CD4-protein in concentrations of 1 to 10 micrograms/ml inhibited the virus-induced syncytium formation, HIV replication in cell culture, synthesis of HIV reverse transcriptase and other virus-specific proteins, that is, behaved as a HIV inhibitor.

Antibodies, Monoclonal↗
PubMedDate not supplied

[The isolation and characteristics of monoclonal antibodies to recombinant proteins of HIV-1 and HIV-2--the env and gag gene products].

Ten hybridomas secreting monoclonal antibodies (Mab) against recombinant HIV-1 and HIV-2 antigens were produced (3 Mab anti-gag protein, 2 anti-env1, and 5 anti-env2). In the immunoblotting assay all the anti-gag Mabs reacted with HIV capsid protein p24, whereas one of them reacted also with p55 protein and with 7 other polypeptides. Another anti-gag Mab cross-reacted with the antigen of subpopulation of human peripheral blood lymphocytes. The third one interacted with the antigen of both HIV-1 and HIV-2. All the 10 Mabs interacted with natural HIV antigens and can be used for identification and differentiation of HIV-1 and HIV-2.

Animals↗
PubMedDate not supplied

[Lissaviruses].

Explore the source record for details and available documents.

Animals↗